Biogen has agreed to acquire Reata Pharmaceuticals for approximately $7.3 billion, the companies said, in a deal intended to bolster the buyer’s neurological drug portfolio with Reata’s recently-approved treatment for Friedreich’s ataxia (FA), whose commercial launch in the U.S….
Source: www.genengnews.com – Read more
VHH Antibodies: Small Size. Big Possibilities.
View eBook This guide shows how single-domain antibodies can unlock crypitic epitopes, streamline CAR-T design, and sepped up the path to multispecific biologics. Why VHH
